Clinical significance of galectin-7 in vulvar squamous cell carcinoma

Jiang,Ying; Tian,Ruoyang; Yu,Shuang; Zhao,Yi; Chen,Yang; Li,Hui; Qiao,Ying; Wu,Xin

doi:10.3892/ol.2015.3826

Clinical significance of galectin-7 in vulvar squamous cell carcinoma

Authors:
- Ying Jiang
- Ruoyang Tian
- Shuang Yu
- Yi Zhao
- Yang Chen
- Hui Li
- Ying Qiao
- Xin Wu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Central Laboratory, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: October 22, 2015 https://doi.org/10.3892/ol.2015.3826
Pages: 3826-3831
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports the role of galectin-7 (Gal-7) expression in vulvar squamous cell carcinoma (VSCC) and its correlation with clinicopathological variables. Gal-7 expression was immunohistochemically detected in the paraffin‑embedded sections of 20 normal vulvar biopsy samples and 50 VSCC specimens. Expression was also detected in 10 normal vulvar biopsy samples and 10 VSCC specimens by western blotting. In addition, the methylation status of the promoter of the Gal‑7 gene was determined in 30 VSCC specimens and 20 samples of normal vulvar tissue by methylation‑specific polymerase chain reaction. Gal‑7 expression was found to be significantly downregulated in the VSCC tissues compared with the normal vulvar tissues (P<0.05). Downregulation of Gal‑7 was correlated with advanced clinical stage, poor tumor differentiation and regional lymph node metastasis (P<0.05). Furthermore, methylation of the Gal‑7 gene promoter was significantly reduced in the vulvar normal tissues compared with the VSCC tissues (P=0.023), while increased Gal‑7 promoter methylation was correlated with advanced clinical stage, poor tumor differentiation and regional lymph node metastasis (P<0.05). There was no association between patient age and Gal‑7 promoter methylation. Together, these results suggested that Gal‑7 has a negative impact in patients with VSCC, with malignant potential correlating with Gal-7 promoter methylation.

View Figures

View References

1	Coulter J and Gleeson N: Local and regional recurrence of vulvar cancer: Management dilemmas. Best Pract Res Clin Obstet Gynaecol. 17:663–681. 2003. View Article : Google Scholar : PubMed/NCBI
2	Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005. View Article : Google Scholar : PubMed/NCBI
3	Magnaldo T, Fowlis D and Darmon M: Galectin-7, a marker of all types of stratified epithelia. Differentiation. 63:159–168. 1998. View Article : Google Scholar : PubMed/NCBI
4	Yang RY and Liu FT: Galectins in cell growth and apoptosis. Cell Mol Life Sci. 60:267–276. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L and Pei HP: Roles of galectin-7 and S100A9 in cervical squamous carcinoma: Clinicopathological and in vitro evidence. Int J Cancer. 132:1051–1059. 2013. View Article : Google Scholar : PubMed/NCBI
6	Rorive S, Eddafali B, Fernandez S, Decaestecker C, André S, Kaltner H, Kuwabara I, Liu FT, Gabius HJ, Kiss R and Salmon I: Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: Diagnostic and biological implications. Mod Pathol. 15:1294–1301. 2002. View Article : Google Scholar : PubMed/NCBI
7	Takata T, Ishigaki Y, Shimasaki T, Tsuchida H, Motoo Y, Hayashi A and Tomosugi N: Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Oncol Rep. 28:1968–1976. 2012.PubMed/NCBI
8	Zhu X, Ding M, Yu ML, Feng MX, Tan LJ and Zhao FK: Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer. 10:2902010. View Article : Google Scholar : PubMed/NCBI
9	Ohno T, Nakano T, Niibe Y, Tsujii H and Oka K: Bax protein expression correlates with radiation-induced apoptosis in radiation therapy for cervical carcinoma. Cancer. 83:103–110. 1998. View Article : Google Scholar : PubMed/NCBI
10	Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B: A model for p53-induced apoptosis. Nature. 389:300–305. 1997. View Article : Google Scholar : PubMed/NCBI
11	Benvenuto G, Carpentieri ML, Salvatore P, Cindolo L, Bruni CB and Chiariotti L: Cell-specific transcriptional regulation and reactivation of galectin-1 gene expression are controlled by DNA methylation of the promoter region. Mol Cell Biol. 16:2736–2743. 1996. View Article : Google Scholar : PubMed/NCBI
12	Ruebel KH, Jin L, Qian X, Scheithauer BW, Kovacs K, Nakamura N, Zhang H, Raz A and Lloyd RV: Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 65:1136–1140. 2005. View Article : Google Scholar : PubMed/NCBI
13	Gendronaneau G, Sidhu SS, Delacour D, Dang T, Calonne C, Houzelstein D, Magnaldo T and Poirier F: Galectin-7 in the control of epidermal homeostasis after injury. J Mol Biol Cell. 19:5541–5549. 2008. View Article : Google Scholar
14	Bernerd F, Sarasin A and Maagnaldo T: Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocaytes. Proc Natl Acad Sci USA. 96:11329–11334. 1999. View Article : Google Scholar : PubMed/NCBI
15	Kopitz J, André S, von Reitzenstein C, Versluis K, Kaltner H, Pieters RJ, Wasano K, Kuwabara I, Liu FT, Cantz M, et al: Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene. 22:6277–6288. 2003. View Article : Google Scholar : PubMed/NCBI
16	Menkhorst EM, Gamage T, Cuman C, Kaitu'u-Lino TJ, Tong S and Dimitriadis E: Glectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. Placenta. 35:195–201. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chen J, He QY, Yuen AP and Chiu JF: Proteomics of buccal squamous cell carcinoma: The involvement of multiple pathways in tumorigenesis. Proteomics. 4:2465–2475. 2004. View Article : Google Scholar : PubMed/NCBI
18	Saussez S, Decaestecker C, Lorfevre F, Chevalier D, Mortuaire G, Kaltner H, André S, Toubeau G, Gabius HJ and Leroy X: Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and −7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology. 52:483–493. 2008. View Article : Google Scholar : PubMed/NCBI
19	Park JE, Chang WY and Choa M: Induction of matrix ametalloproteinase-9 by galectin-7 through p38 MAPK signaaling in HeLa human cervical epithelial adenocarcinoma cells. Oncol Rep. 22:1373–1379. 2009.PubMed/NCBI
20	Kim HJ, Jeon HK, Lee JK, Sung CO, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS and Lee JW: Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res. 33:1555–1561. 2013.PubMed/NCBI
21	Kim SJ, Hwang JA, Ro JY, Lee YS and Chun KH: Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget. 4:1461–1471. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kuwabara I, Kuwabara Y, Yang R, Schuler M, Green D, Zuraw B, Hsu D and Liu F: Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem. 277:3487–3497. 2002. View Article : Google Scholar : PubMed/NCBI
23	Villeneuve C, Baricault L, Canelle L, Barboule N, Racca C, Monsarrat B, Magnaldo T and Larminat F: Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell. 22:999–1013. 2011. View Article : Google Scholar : PubMed/NCBI
24	Barkan B, Cox AD and Kloog Y: Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. Oncotarget. 4:256–268. 2013. View Article : Google Scholar : PubMed/NCBI
25	Ueda S, Kuwabara I and Liu FT: Suppression of tumor growth by galectin-7 gene transfer. Cancer Res. 64:5672–5676. 2004. View Article : Google Scholar : PubMed/NCBI
26	Rossi NE, Reiné J, Pineda-Lezamit M, Pulgar M, Meza NW, Swamy M, Risueno R, Schamel WW, Bonay P, Fernández-Malavé E and Regueiro JR: Differential antibody binding to the surface alphabetaTCR. CD3 complex of CD4+ and CD8+ T lymphocytes is conserved in mammals and associated with differential glycosylation. Int Immunol. 20:1247–1258. 2008. View Article : Google Scholar : PubMed/NCBI
27	Demers M, Couillard J, Giglia-Mari G, Magnaldo T and St-Pierre Y: Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation. Biochem Biophys Res Commun. 387:425–429. 2009. View Article : Google Scholar : PubMed/NCBI
28	Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF and St-Pierre Y: Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia. 17:751–759. 2003. View Article : Google Scholar : PubMed/NCBI